Novartis extends deal to make Pfizer/BioNTech vaccines

Reuters2021-10-21

ZURICH, Oct 21 (Reuters) - Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech,COVID-19 vaccine by using manufacturing facilities Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Thursday.

Novartis plans to take bulk mRNA active ingredient from BioNTech and fill this into vials under sterile conditions for shipment back to BioNTech for distribution.

This new agreement follows an earlier deal for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
5